These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 20560786)
1. Ajoene, a stable garlic by-product, inhibits high fat diet-induced hepatic steatosis and oxidative injury through LKB1-dependent AMPK activation. Han CY; Ki SH; Kim YW; Noh K; Lee DY; Kang B; Ryu JH; Jeon R; Kim EH; Hwang SJ; Kim SG Antioxid Redox Signal; 2011 Jan; 14(2):187-202. PubMed ID: 20560786 [TBL] [Abstract][Full Text] [Related]
2. Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones. Hwahng SH; Ki SH; Bae EJ; Kim HE; Kim SG Hepatology; 2009 Jun; 49(6):1913-25. PubMed ID: 19378344 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of SREBP-1c-mediated hepatic steatosis and oxidative stress by sauchinone, an AMPK-activating lignan in Saururus chinensis. Kim YW; Kim YM; Yang YM; Kim TH; Hwang SJ; Lee JR; Kim SC; Kim SG Free Radic Biol Med; 2010 Feb; 48(4):567-78. PubMed ID: 20005944 [TBL] [Abstract][Full Text] [Related]
4. Rimonabant, a cannabinoid receptor type 1 inverse agonist, inhibits hepatocyte lipogenesis by activating liver kinase B1 and AMP-activated protein kinase axis downstream of Gα i/o inhibition. Wu HM; Yang YM; Kim SG Mol Pharmacol; 2011 Nov; 80(5):859-69. PubMed ID: 21803969 [TBL] [Abstract][Full Text] [Related]
5. Honokiol activates the LKB1-AMPK signaling pathway and attenuates the lipid accumulation in hepatocytes. Seo MS; Kim JH; Kim HJ; Chang KC; Park SW Toxicol Appl Pharmacol; 2015 Apr; 284(2):113-24. PubMed ID: 25737164 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of liver X receptor-α-dependent hepatic steatosis by isoliquiritigenin, a licorice antioxidant flavonoid, as mediated by JNK1 inhibition. Kim YM; Kim TH; Kim YW; Yang YM; Ryu DH; Hwang SJ; Lee JR; Kim SC; Kim SG Free Radic Biol Med; 2010 Dec; 49(11):1722-34. PubMed ID: 20840863 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of LXRα-dependent steatosis and oxidative injury by liquiritigenin, a licorice flavonoid, as mediated with Nrf2 activation. Kim YW; Kim YM; Yang YM; Kay HY; Kim WD; Lee JW; Hwang SJ; Kim SG Antioxid Redox Signal; 2011 Mar; 14(5):733-45. PubMed ID: 20677908 [TBL] [Abstract][Full Text] [Related]
8. Retinoic acid receptor-related orphan receptor α-induced activation of adenosine monophosphate-activated protein kinase results in attenuation of hepatic steatosis. Kim EJ; Yoon YS; Hong S; Son HY; Na TY; Lee MH; Kang HJ; Park J; Cho WJ; Kim SG; Koo SH; Park HG; Lee MO Hepatology; 2012 May; 55(5):1379-88. PubMed ID: 22183856 [TBL] [Abstract][Full Text] [Related]
9. Nectandrin B, a lignan isolated from nutmeg, inhibits liver X receptor-α-induced hepatic lipogenesis through AMP-activated protein kinase activation. Choi du G; Kim EK; Yang JW; Song JS; Kim YM Pharmazie; 2015 Nov; 70(11):733-9. PubMed ID: 26790190 [TBL] [Abstract][Full Text] [Related]
10. An active metabolite of oltipraz (M2) increases mitochondrial fuel oxidation and inhibits lipogenesis in the liver by dually activating AMPK. Kim TH; Eom JS; Lee CG; Yang YM; Lee YS; Kim SG Br J Pharmacol; 2013 Apr; 168(7):1647-61. PubMed ID: 23145499 [TBL] [Abstract][Full Text] [Related]
11. Resveratrol inhibits LXRα-dependent hepatic lipogenesis through novel antioxidant Sestrin2 gene induction. Jin SH; Yang JH; Shin BY; Seo K; Shin SM; Cho IJ; Ki SH Toxicol Appl Pharmacol; 2013 Aug; 271(1):95-105. PubMed ID: 23651738 [TBL] [Abstract][Full Text] [Related]
12. Piperine reverses high fat diet-induced hepatic steatosis and insulin resistance in mice. Choi S; Choi Y; Choi Y; Kim S; Jang J; Park T Food Chem; 2013 Dec; 141(4):3627-35. PubMed ID: 23993530 [TBL] [Abstract][Full Text] [Related]
13. Oxyresveratrol ameliorates nonalcoholic fatty liver disease by regulating hepatic lipogenesis and fatty acid oxidation through liver kinase B1 and AMP-activated protein kinase. Lee JH; Baek SY; Jang EJ; Ku SK; Kim KM; Ki SH; Kim CE; Park KI; Kim SC; Kim YW Chem Biol Interact; 2018 Jun; 289():68-74. PubMed ID: 29702089 [TBL] [Abstract][Full Text] [Related]
14. Combination of honokiol and magnolol inhibits hepatic steatosis through AMPK-SREBP-1 c pathway. Lee JH; Jung JY; Jang EJ; Jegal KH; Moon SY; Ku SK; Kang SH; Cho IJ; Park SJ; Lee JR; Zhao RJ; Kim SC; Kim YW Exp Biol Med (Maywood); 2015 Apr; 240(4):508-18. PubMed ID: 25125496 [TBL] [Abstract][Full Text] [Related]
15. SIRT1 activation by methylene blue, a repurposed drug, leads to AMPK-mediated inhibition of steatosis and steatohepatitis. Shin SY; Kim TH; Wu H; Choi YH; Kim SG Eur J Pharmacol; 2014 Mar; 727():115-24. PubMed ID: 24486702 [TBL] [Abstract][Full Text] [Related]
16. Ginsenoside Re lowers blood glucose and lipid levels via activation of AMP-activated protein kinase in HepG2 cells and high-fat diet fed mice. Quan HY; Yuan HD; Jung MS; Ko SK; Park YG; Chung SH Int J Mol Med; 2012 Jan; 29(1):73-80. PubMed ID: 21971952 [TBL] [Abstract][Full Text] [Related]
17. 3-Caffeoyl, 4-dihydrocaffeoylquinic acid from Salicornia herbacea attenuates high glucose-induced hepatic lipogenesis in human HepG2 cells through activation of the liver kinase B1 and silent information regulator T1/AMPK-dependent pathway. Pil Hwang Y; Gyun Kim H; Choi JH; Truong Do M; Tran TP; Chun HK; Chung YC; Jeong TC; Jeong HG Mol Nutr Food Res; 2013 Mar; 57(3):471-82. PubMed ID: 23349077 [TBL] [Abstract][Full Text] [Related]
18. GPR119: a promising target for nonalcoholic fatty liver disease. Yang JW; Kim HS; Im JH; Kim JW; Jun DW; Lim SC; Lee K; Choi JM; Kim SK; Kang KW FASEB J; 2016 Jan; 30(1):324-35. PubMed ID: 26399788 [TBL] [Abstract][Full Text] [Related]
19. S-allyl cysteine attenuates free fatty acid-induced lipogenesis in human HepG2 cells through activation of the AMP-activated protein kinase-dependent pathway. Hwang YP; Kim HG; Choi JH; Do MT; Chung YC; Jeong TC; Jeong HG J Nutr Biochem; 2013 Aug; 24(8):1469-78. PubMed ID: 23465592 [TBL] [Abstract][Full Text] [Related]
20. Thyrotropin increases hepatic triglyceride content through upregulation of SREBP-1c activity. Yan F; Wang Q; Lu M; Chen W; Song Y; Jing F; Guan Y; Wang L; Lin Y; Bo T; Zhang J; Wang T; Xin W; Yu C; Guan Q; Zhou X; Gao L; Xu C; Zhao J J Hepatol; 2014 Dec; 61(6):1358-64. PubMed ID: 25016220 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]